Drugs / Trimebutine
Trimebutine
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06268964 | Sep → Dec 2024 overdue | irritable bowel syndrome | University of Colima | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03359499 | Aug → Oct 2017 | irritable bowel syndrome | Hospital Britanico | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01984931 | Oct → Dec 2013 | — | CM Chungmu Hospital | Unknown | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05379036 | Jun 2021 → May 2022 | irritable bowel syndrome | I.M. Sechenov First Moscow State Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT04403087 | May → Jun 2021 | Helicobacter pylori infectious disease | Chuncheon Sacred Heart Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02986685 | Nov 2016 → Oct 2017 | peptic esophagitis | Xijing Hospital of Digestive Diseases | Withdrawn | No outcome recorded Stop: Business |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT07688161 Comparator | Jul 2026 → Jan 2028 expected | irritable bowel syndrome | Nanjing First Hospital, Nanjing Medical University | Not yet recruiting | No outcome recorded |
| — | NCT03036111 Comparator | Feb 2017 → Feb 2018 | hemorrhoid | Mansoura University | Suspended | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trimebutine | “Patients in group 1 received Trimedat (trimebutine, marketing authorization number LP-005534/07 of 2007-12-28) for 2 months” NCT05379036 ↗ |
| Known as | Trimebutina | ChEMBL registry synonym — accepted as the source's own label CHEMBL190044 ↗ |
| Known as | trimebutine maleate | “then oral trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily were administered” NCT02986685 ↗2“Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)is a noncompetitive spasmolytic agent.” NCT01984931 ↗ |
| Known as | Trimedat | “Patients in group 1 received Trimedat (trimebutine, marketing authorization number LP-005534/07 of 2007-12-28) for 2 months” NCT05379036 ↗ |
| Modality | Small molecule | — CHEMBL190044 ↗ |
| Route | Oral | “A single dose of NEWBUTIN SR 300 mg Tab will be given orally one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.” NCT01984931 ↗ |